Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:14:09 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



Q:CORT - CORCEPT THERAPEUTICS INC - http://www.corcept.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CORT - Q0.224.59·27.660.124.52-0.54-2.21,698.340,05314,27225.06  25.22  23.1134.275  20.8418:13:30May 0115 min RT 2¢

Recent Trades - Last 10 of 14272
Time ETExPriceChangeVolume
18:13:30Q25.00-0.06400
16:53:20Q25.06 1
16:53:20Q25.06 1
16:42:07Q24.931-0.1291
16:42:07Q24.931-0.1292
16:30:09Q24.60-0.4610
16:04:56Q24.52-0.541,502
16:04:49Q24.52-0.542,639
16:03:12Q24.87-0.193
16:03:12Q24.88-0.183

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-01 16:05U:CORTNews ReleaseCorcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
2024-04-29 08:00U:CORTNews ReleaseCorcept Completes Enrollment in Phase 4 CATALYST Trial
2024-04-24 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
2024-04-22 08:00U:CORTNews ReleaseCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing's Syndrome
2024-04-15 08:00U:CORTNews ReleaseCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
2024-04-08 08:00U:CORTNews ReleaseCorcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
2024-04-01 08:00U:CORTNews ReleaseCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome
2024-02-15 16:07U:CORTNews ReleaseCorcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
2024-02-15 16:02U:CORTNews ReleaseCorcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
2024-02-08 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
2024-01-29 08:00U:CORTNews ReleaseCorcept Appoints Roberto Vieira as President, Oncology
2024-01-08 08:00U:CORTNews ReleaseCorcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
2024-01-02 08:00U:CORTNews ReleaseCourt Finds Corcept Therapeutics ¢ € ™ Patents Not Infringed
2023-11-01 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
2023-11-01 08:00U:CORTNews ReleaseCorcept Appoints Monica Tellado as President, Emerging Markets
2023-10-26 16:05U:CORTNews ReleaseCorcept Initiates MONARCH ¢ € “ A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
2023-10-25 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
2023-08-02 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
2023-07-26 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
2023-07-17 16:05U:CORTNews ReleaseCorcept ¢ € ™s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)